 DURHAM, N.C., March 11, 2021 GLOBE NEWSWIRE -- Bioventus Inc. Nasdaq: BVS Bioventus or the Company, a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study of MOTYS PTP-001 with Dr. Shailesh Patel, M.D. at Coastal Carolina Research Center, South Carolina. MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form. 